Shares of Verastem (NASDAQ:VSTM) have been given an average rating of “Buy” by the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.94.
Several brokerages have recently weighed in on VSTM. B. Riley set a $15.00 target price on Verastem and gave the stock a “buy” rating in a research note on Friday, March 23rd. Zacks Investment Research downgraded Verastem from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. HC Wainwright set a $10.00 price objective on Verastem and gave the company a “buy” rating in a research note on Thursday, March 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price objective on shares of Verastem in a research note on Tuesday, March 13th. Finally, Cann reissued a “buy” rating and issued a $13.00 price objective on shares of Verastem in a research note on Friday, January 26th.
Shares of VSTM stock traded down $0.08 during trading hours on Friday, hitting $2.96. 546,146 shares of the company’s stock were exchanged, compared to its average volume of 518,363. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.13 and a quick ratio of 5.13. The company has a market cap of $150.37, a price-to-earnings ratio of -1.68 and a beta of 2.23. Verastem has a fifty-two week low of $1.61 and a fifty-two week high of $5.71.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL acquired a new position in Verastem in the 4th quarter valued at $6,908,000. Point72 Asset Management L.P. purchased a new stake in Verastem in the 3rd quarter valued at $6,580,000. Vanguard Group Inc. grew its holdings in Verastem by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock valued at $2,493,000 after buying an additional 107,029 shares in the last quarter. Artal Group S.A. grew its holdings in Verastem by 33.3% in the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $3,070,000 after buying an additional 250,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Verastem by 93.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 561,969 shares of the biopharmaceutical company’s stock valued at $2,641,000 after buying an additional 272,141 shares in the last quarter. 31.65% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3341904/verastem-vstm-receives-consensus-rating-of-buy-from-analysts.html.
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.